In silico trial for the assessment of givinostat dose adjustment rules based on the management of key hematological parameters in polycythemia vera patients

• প্রধান লেখক: Elena M. Tosca (Author), Alessandro De Carlo (Author), Roberta Bartolucci (Author), Francesco Fiorentini (Author), Silvia Di Tollo (Author), Maurizio Caserini (Author), Maurizio Rocchetti (Author), Paolo Bettica (Author), Paolo Magni (Author)
• বিন্যাস: গ্রন্থ
• প্রকাশিত: Wiley, 2024-03-01T00:00:00Z.
• বিষয়গুলি: article
• অনলাইন ব্যবহার করুন: Connect to this object online.

Abstract Polycythemia vera (PV) is a chronic myeloproliferative neoplasm characterized by excessive levels of platelets (PLT), white blood cells (WBC), and hematocrit (HCT). Givinostat (ITF2357) is a potent histone‐deacetylase inhibitor that showed a good safety/efficacy profile in PV patients durin...